Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
On-Demand Preexposure Prophylaxis
A look at men at high risk for HIV-1 infection
Protection against HIV-1 infection in men who have sex with men was provided by the use of tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) before and after sexual activity in a randomized trial of antiretroviral therapy. The 414 participants were randomized to either the TDF-FTC group or the placebo group. Both groups received risk-reduction counseling and condoms, were regularly tested for HIV-1 and HIV-2 and other STIs, and were followed for a median of 9.3 months. Researchers found:
• A total of 16 HIV-1 infections occurred during follow-up; 2 in the TDF-FTC group and 14 in the placebo group (RR=86%).
• Rates of serious adverse events were similar in the 2 study groups.
• There were higher rates of gastrointestinal adverse events (14% vs 5%) and renal adverse events (18% vs 10%) in the TDF-FTC group when compared with the placebo group.
Citation: Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-2246. doi: 10.1056/NEJMoa1506273.
1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410. doi: 10.1056/NEJMoa1108524.